Delmar Pharma (DMPI) 0.5900 $DMPI
DelMar Pharmaceuticals to Present Updated Phase I/II Clinical Data on VAL-083 in the Treatment of Refractory Glioblastoma Multiforme at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma
PR Newswire - Thu Jul 09, 6:35AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
, a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that the Company will be presenting updated clinical data on its lead product candidate, VAL-083, from its Phase I/II clinical trial in patients with refractory glioblastoma multiforme (GBM), the most common and deadly form of human brain cancer.
SeeThruEquity Issues Update on DelMar Pharmaceuticals Highlighting Encouraging Efficacy Data Presented at ASCO
ACCESSWIRE - Thu Jun 25, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / June 25, 2015 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar Pharmaceuticals, Inc. (OTCQX: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.
Week In Review: Livzon Leads $26 Million Funding Of Cynvenio
ChinaBio Today - at Seeking Alpha - Sun Jun 21, 4:57AM CDT
Deals and Financings Livzon Pharma (SZ: 000513 HK: 01513) of Zuhai, China, led a $25.5 million Series B funding of Cynvenio Biosystems, a Los Angeles area diagnostics company. Cynvenio is developing LiquidBiopsy, a technology that performs genomic...
JNJ: 99.53 (+1.13), GILD: 113.74 (+0.38), PFE: 34.36 (+0.50), WX: 40.50 (+0.96)
DelMar Pharmaceuticals Invited to Present at The World NSCLC Summit on June 23-24, 2015
PR Newswire - Mon Jun 15, 7:05AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that it has been invited to present at The World NSCLC Summit being held June 23-24, 2015 in Boston, MA.
DelMar Pharmaceuticals to Present at the BIO International Convention on June 17, 2015
PR Newswire - Wed Jun 10, 7:35AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that it will be presenting at the BIO International Convention being held June 15-18, 2015, in Philadelphia, PA.
Del Mar Pharmaceuticals Inc. (DMPI) to Present at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on June 10
GlobeNewswire - Thu Jun 04, 7:02AM CDT
Del Mar Pharmaceuticals Inc. (OTCMKTS
MPI), a biopharmaceutical development and exploration company, will be presenting at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on Wednesday, June 10. The event is a gathering of the brightest emerging growth small-cap and pre-IPO companies to present and network with an exclusive group of top-level institutional investors.
DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO
PR Newswire - Mon Jun 01, 1:29PM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced updated clinical data from its Phase I/II clinical trial of VAL-083 (dianhydrogalactitol) in patients with refractory glioblastoma multiforme (GBM), the most common and deadly form of human brain cancer.
DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme
PR Newswire - Mon Jun 01, 7:35AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, announced that it will be hosting a business update conference call and live webcast today, June 1, 2015, at 5:30 p.m. CDT (6:30 p.m. EDT).
DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme
PR Newswire - Fri May 29, 6:35AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, presented additional preclinical data at the American Association of Cancer Research (AACR) Advances in Brain Cancer Research Conference on the potential for its lead product candidate VAL-083 (dianhydrogalactitol) to treat patients with temozolomide-resistant glioblastoma multiforme (GBM).
DelMar Pharmaceuticals Announces Upcoming Investor and Scientific Conference Presentations
PR Newswire - Wed May 27, 6:05AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that it will be presenting at several upcoming investor and scientific conferences.
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2015 Financial Results and Provides Corporate Update
PR Newswire - Mon May 18, 7:05AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced its financial results for the three and nine months ending March 31, 2015 and provided an overview of recent Company highlights and expected near-term milestones.
SeeThruEquity Issues Update on DelMar Pharmaceuticals Highlighting Data Presented at American Association for Cancer Research
ACCESSWIRE - Tue May 12, 8:02AM CDT
NEW YORK, NY / ACCESSWIRE / May 12, 2015 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a 2Q15 update note on DelMar Pharmaceuticals, Inc. (OTCQX: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.
DelMar Pharmaceuticals to Present Additional Data on VAL-083 as a Potential Treatment for Temozolomide-Resistant GBM at AACR Advances in Brain Cancer Research Conference
PR Newswire - Thu May 07, 7:05AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that it will be presenting additional data on VAL-083 (dianhydrogalactitol) as a potential new treatment for temozolomide-resistant glioblastoma multiforme (GBM) at the American Association for Cancer Research (AACR) Advances in Brain Cancer Research conference being held May 27-30, 2015, in Washington, DC.
DelMar Pharmaceuticals to Present Data Supporting the Development of VAL-083 in Refractory Glioblastoma Multiforme and Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
PR Newswire - Thu Apr 30, 6:05AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", today announced that it will be presenting new data related to the development of lead product candidate VAL-083 (dianhydrogalactitol) at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29-June 2, 2015, in Chicago, Illinois.
DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM)
PR Newswire - Mon Apr 20, 12:00PM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced promising preclinical data at the 106th Annual Meeting of the American Association for Cancer Research (AACR) Annual Meeting on the potential for its lead product candidate VAL-083 (dianhydrogalactitol) to treat patients with temozolomide-resistant glioblastoma multiforme (GBM).
DelMar Pharmaceuticals Presents Updated Clinical Data on Phase I/II Study of VAL-083 in Refractory Glioblastoma Multiforme (GBM)
PR Newswire - Mon Apr 20, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced updated clinical data on the identification of maximum tolerated dose (MTD) from its Phase I/II study of its lead product candidate VAL-083 (dianhydrogalactitol) in patients with refractory glioblastoma multiforme (GBM), the most common and deadly form of human brain cancer.
DelMar Pharmaceuticals Presents Positive Preclinical Data on VAL-083 for Treatment of Non-Small Cell Lung Cancer at the American Association of Cancer Research Annual Meeting
PR Newswire - Sun Apr 19, 12:00PM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced positive preclinical data on its lead product candidate VAL-083 (dianhydrogalactitol) for treatment of platinum drug-resistant non-small cell lung cancer (NSCLC) and as a potential combination therapy option in newly diagnosed NSCLC patients.
DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma
PR Newswire - Thu Apr 16, 7:05AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that the Mayo Clinic Cancer Center has been added as a clinical trial site for the ongoing, multicenter Phase I/II study of VAL-083 in patients with refractory glioblastoma multiforme (GBM), the most common and deadly form of human brain cancer.
DelMar Pharmaceuticals Announces Panel Participation in Cancer Advance Boston Conference on April 14, 2015
PR Newswire - Tue Apr 07, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that Jeffrey Bacha, President and CEO, will be a panelist at Cancer Advance Boston, a networking conference of the Boston Biotech Conference series, being held April 13-14, 2015, at the Joseph B. Martin Conference Center at Harvard Medical School in Boston, Massachusetts.
DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., to the Board of Directors
PR Newswire - Wed Apr 01, 7:05AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", today announced that it has appointed biopharmaceutical industry veteran, Erich Mohr, Ph.D., R.Psych., to its Board of Directors as an independent director.
DelMar Pharmaceuticals to Present Updated Phase I/II Clinical Data on VAL-083 in the Treatment of Refractory Glioblastoma Multiforme at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma
PR Newswire - Thu Jul 09, 6:35AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
, a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that the Company will be presenting updated clinical data on its lead product candidate, VAL-083, from its Phase I/II clinical trial in patients with refractory glioblastoma multiforme (GBM), the most common and deadly form of human brain cancer. SeeThruEquity Issues Update on DelMar Pharmaceuticals Highlighting Encouraging Efficacy Data Presented at ASCO
ACCESSWIRE - Thu Jun 25, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / June 25, 2015 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar Pharmaceuticals, Inc. (OTCQX: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.
Week In Review: Livzon Leads $26 Million Funding Of Cynvenio
ChinaBio Today - at Seeking Alpha - Sun Jun 21, 4:57AM CDT
Deals and Financings Livzon Pharma (SZ: 000513 HK: 01513) of Zuhai, China, led a $25.5 million Series B funding of Cynvenio Biosystems, a Los Angeles area diagnostics company. Cynvenio is developing LiquidBiopsy, a technology that performs genomic...
JNJ: 99.53 (+1.13), GILD: 113.74 (+0.38), PFE: 34.36 (+0.50), WX: 40.50 (+0.96)
DelMar Pharmaceuticals Invited to Present at The World NSCLC Summit on June 23-24, 2015
PR Newswire - Mon Jun 15, 7:05AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
, a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that it has been invited to present at The World NSCLC Summit being held June 23-24, 2015 in Boston, MA. DelMar Pharmaceuticals to Present at the BIO International Convention on June 17, 2015
PR Newswire - Wed Jun 10, 7:35AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
, a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that it will be presenting at the BIO International Convention being held June 15-18, 2015, in Philadelphia, PA. Del Mar Pharmaceuticals Inc. (DMPI) to Present at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on June 10
GlobeNewswire - Thu Jun 04, 7:02AM CDT
Del Mar Pharmaceuticals Inc. (OTCMKTS
MPI), a biopharmaceutical development and exploration company, will be presenting at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on Wednesday, June 10. The event is a gathering of the brightest emerging growth small-cap and pre-IPO companies to present and network with an exclusive group of top-level institutional investors. DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO
PR Newswire - Mon Jun 01, 1:29PM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
, a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced updated clinical data from its Phase I/II clinical trial of VAL-083 (dianhydrogalactitol) in patients with refractory glioblastoma multiforme (GBM), the most common and deadly form of human brain cancer. DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme
PR Newswire - Mon Jun 01, 7:35AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
, a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, announced that it will be hosting a business update conference call and live webcast today, June 1, 2015, at 5:30 p.m. CDT (6:30 p.m. EDT). DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme
PR Newswire - Fri May 29, 6:35AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
, a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, presented additional preclinical data at the American Association of Cancer Research (AACR) Advances in Brain Cancer Research Conference on the potential for its lead product candidate VAL-083 (dianhydrogalactitol) to treat patients with temozolomide-resistant glioblastoma multiforme (GBM). DelMar Pharmaceuticals Announces Upcoming Investor and Scientific Conference Presentations
PR Newswire - Wed May 27, 6:05AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
, a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that it will be presenting at several upcoming investor and scientific conferences. DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2015 Financial Results and Provides Corporate Update
PR Newswire - Mon May 18, 7:05AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
, a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced its financial results for the three and nine months ending March 31, 2015 and provided an overview of recent Company highlights and expected near-term milestones. SeeThruEquity Issues Update on DelMar Pharmaceuticals Highlighting Data Presented at American Association for Cancer Research
ACCESSWIRE - Tue May 12, 8:02AM CDT
NEW YORK, NY / ACCESSWIRE / May 12, 2015 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a 2Q15 update note on DelMar Pharmaceuticals, Inc. (OTCQX: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.
DelMar Pharmaceuticals to Present Additional Data on VAL-083 as a Potential Treatment for Temozolomide-Resistant GBM at AACR Advances in Brain Cancer Research Conference
PR Newswire - Thu May 07, 7:05AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
, a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that it will be presenting additional data on VAL-083 (dianhydrogalactitol) as a potential new treatment for temozolomide-resistant glioblastoma multiforme (GBM) at the American Association for Cancer Research (AACR) Advances in Brain Cancer Research conference being held May 27-30, 2015, in Washington, DC. DelMar Pharmaceuticals to Present Data Supporting the Development of VAL-083 in Refractory Glioblastoma Multiforme and Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
PR Newswire - Thu Apr 30, 6:05AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
, today announced that it will be presenting new data related to the development of lead product candidate VAL-083 (dianhydrogalactitol) at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29-June 2, 2015, in Chicago, Illinois. DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM)
PR Newswire - Mon Apr 20, 12:00PM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced promising preclinical data at the 106th Annual Meeting of the American Association for Cancer Research (AACR) Annual Meeting on the potential for its lead product candidate VAL-083 (dianhydrogalactitol) to treat patients with temozolomide-resistant glioblastoma multiforme (GBM).
DelMar Pharmaceuticals Presents Updated Clinical Data on Phase I/II Study of VAL-083 in Refractory Glioblastoma Multiforme (GBM)
PR Newswire - Mon Apr 20, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced updated clinical data on the identification of maximum tolerated dose (MTD) from its Phase I/II study of its lead product candidate VAL-083 (dianhydrogalactitol) in patients with refractory glioblastoma multiforme (GBM), the most common and deadly form of human brain cancer.
DelMar Pharmaceuticals Presents Positive Preclinical Data on VAL-083 for Treatment of Non-Small Cell Lung Cancer at the American Association of Cancer Research Annual Meeting
PR Newswire - Sun Apr 19, 12:00PM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced positive preclinical data on its lead product candidate VAL-083 (dianhydrogalactitol) for treatment of platinum drug-resistant non-small cell lung cancer (NSCLC) and as a potential combination therapy option in newly diagnosed NSCLC patients.
DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma
PR Newswire - Thu Apr 16, 7:05AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that the Mayo Clinic Cancer Center has been added as a clinical trial site for the ongoing, multicenter Phase I/II study of VAL-083 in patients with refractory glioblastoma multiforme (GBM), the most common and deadly form of human brain cancer.
DelMar Pharmaceuticals Announces Panel Participation in Cancer Advance Boston Conference on April 14, 2015
PR Newswire - Tue Apr 07, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that Jeffrey Bacha, President and CEO, will be a panelist at Cancer Advance Boston, a networking conference of the Boston Biotech Conference series, being held April 13-14, 2015, at the Joseph B. Martin Conference Center at Harvard Medical School in Boston, Massachusetts.
DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., to the Board of Directors
PR Newswire - Wed Apr 01, 7:05AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
, today announced that it has appointed biopharmaceutical industry veteran, Erich Mohr, Ph.D., R.Psych., to its Board of Directors as an independent director. 
